NCT04603833Unknown2 期
A Phase II Clinical Study of SHR3680 Combined With Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer Previously Treated With Abiraterone
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Time to prostate specific antigen (PSA) progression
研究概览
简要总结
The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific antigen (PSA) progression is superior to SHR3680 or Docetaxel single drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed prostate cancer; Unconfirmed neuroendocrine carcinoma or small cell carcinoma;
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1;
- •Radiographic evidence of metastasis（CT/MRI/ECT);
- •Sustained therapy of luteinizing hormone-releasing hormone analogue(LHRHA)or received bilateral orchiectomy; patients who did not receive bilateral orchiectomy are willing to receive sustained therapy of LHRHA;
- •Evidence of prostate cancer progression under the sustained therapy of LHRHA or bilateral orchiectomy;
- •Adequate hepatic, renal, heart, and hematological functions;
- •Patients have given voluntary written informed consent before performance of any study-related procedure not part of normal medical care,with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care；
- •Expected to survive for at least 3 months；
- •Patient has been treated with Abiraterone and treatment failed；Treatment failure is defined as the progression of disease during treatment；
排除标准
- •Have received any anti-tumor therapy in the past 4 weeks,including radiotherapy, chemotherapy, operation, targeted therapy, immuntherapy, and endocrinotherapy;
- •As a subject to participate in other drug clinical trials, the last test drug was administered within 4 weeks from the first dose of the study drug;
- •Plan to receive any other anti-tumor treatment during this trial;
- •Subjects have contraindications to prednisone, such as active infections or other conditions;
- •Subjects present any chronic condition requiring treatment with corticosteroids at doses greater than prednisone 5 mg, BID;
- •The investigators judged severe bone damage caused by tumor bone metastasis, including severely controlled bone pain, pathological fractures and spinal cord compressions that occurred in the last 6 months or are expected to occur in the near future;
- •Uncontrolled high blood pressure (systolic blood pressure 160 mmHg or diastolic blood pressure 95 mmHg). If blood pressure can be effectively controlled by antihypertensive therapy, subjects with a history of hypertension are allowed to participate in the study;
- •Study of active heart disease within 6 months prior to the first dose, including: severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, left ventricular ejection fraction <50%, and room for medication Arrhythmia;
- •Imaging diagnosis of brain tumor lesions;
- •history of pituitary or adrenal dysfunction;
- •Study of other malignant tumors within 5 years prior to the first dose (in situ cancer with complete remission and excluding malignant tumors with slow progress);
- •Patients with active HBV or HCV infection (HBV virus copy number #104 copies/mL, HCV virus copy number #103 copies/mL), or active syphilis infection;
- •History of immunodeficiency (including HIV positive, other acquired, congenital immunodeficiency disease) or organ transplant history;
- •Habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease; abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months before the first dose;
- •Patients who are unwilling to take effective contraceptive measures during the entire study period and within 3 months after the last dose
研究组 & 干预措施
SHR3680
Active Comparator
干预措施: SHR3680 (Drug)
Docetaxel
Active Comparator
干预措施: Docetaxel (Drug)
SHR3680+Docetaxel
Experimental
干预措施: SHR3680+Docetaxel (Drug)
结局指标
主要结局
Time to prostate specific antigen (PSA) progression
时间窗: [Time Frame: Approximately 24 months]
Time from randomisation to the first time of PSA progression according to the criterion of PCGW3
Adverse Event(AE)
时间窗: [Time Frame: Approximately 24 months]
The type, frequency, severity, timing, seriousness, and relationship to study therapy
次要结局
- Objective response rate (ORR)([Time Frame: Approximately 24 months])
- PSA response rate([Time Frame: Approximately 3 months])
- Overall Survival(OS)([Time Frame: Approximately 24 months])
- Area Under the Curve (AUC)([Time Frame: Approximately 2 months])
- Radiographic Progression Free Survival(rPFS)([Time Frame: Approximately 24 months])
- Maximum Observed Plasma Concentration (Cmax)([Time Frame: Approximately 2 months])
- Minimum Observed Plasma Concentration (Cmin)([Time Frame: Approximately 2 months])
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPCCastration-resistant Prostate CancerProstate CancerNCT04102124Jiangsu HengRui Medicine Co., Ltd.20
终止
3 期
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerNon Squamous Non Small Cell LungNCT02766140Jiangsu HengRui Medicine Co., Ltd.12
已完成
1 期
A Study of ARRY-334543 and Docetaxel in Patients With Advanced CancerAdvanced CancerNCT00833326Array Biopharma, now a wholly owned subsidiary of Pfizer27
已完成
2 期
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT04676607The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School6
终止
2 期
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLCCarcinoma, Non-Small-Cell LungLung CancerNCT00238615Stanford University13